Warum steigt der Aktienkurs von MERCK & CO.?
Bullen sagen
MRNA oncology validation
A successful Phase 3 individualized mRNA cancer vaccine would validate the neoantigen platform and enable expansion of the technology into multiple tumor types.
Tulisokibart efficacy and safety
Strong mid-stage results showing meaningful patient responses and a clean safety profile for tulisokibart would support advancement into pivotal studies and highlight competitive potential in hidradenitis suppurativa.
Lipfendra commercial adoption
Widespread uptake of Lipfendra as a once-daily oral PCSK9 inhibitor would demonstrate demand for an oral alternative to injectables and could broaden the cholesterol-lowering market opportunity.
Keytruda loss of exclusivity
Loss of exclusivity for Keytruda remains a significant overhang that could pressure future revenue and company valuation despite pipeline progress.
Remigromig safety concerns
Elevated rates of serious ocular events and treatment discontinuations reported with remigromig versus the comparator raise adoption and regulatory risk that could constrain commercial uptake.
Pricing and profitability pressure
Pricing pressure in major European markets combined with continued heavy investment in product launches and clinical development is likely to weigh on profitability and earnings momentum.
